<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31527692</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>29</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>04</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Sep</Month><Day>16</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>VRK1 functional insufficiency due to alterations in protein stability or kinase activity of human VRK1 pathogenic variants implicated in neuromotor syndromes.</ArticleTitle><Pagination><StartPage>13381</StartPage><MedlinePgn>13381</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">13381</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-019-49821-7</ELocationID><Abstract><AbstractText>Very rare polymorphisms in the human VRK1 (vaccinia-related kinase 1) gene have been identified in complex neuromotor phenotypes associated to spinal muscular atrophy (SMA), pontocerebellar hypoplasia (PCH), microcephaly, amyotrophic lateral sclerosis (ALS) and distal motor neuron dysfunctions. The mechanisms by which these VRK1 variant proteins contribute to the pathogenesis of these neurological syndromes are unknown. The syndromes are manifested when both of these rare VRK1 polymorphic alleles are implicated, either in homozygosis or compound heterozygosis. In this report, to identify the common underlying pathogenic mechanism of VRK1 polymorphisms, we have studied all human VRK1 variants identified in these neurological phenotypes from a biochemical point of view by molecular modeling, protein stability and kinase activity assays. Molecular modelling predicted that VRK1 variant proteins are either unstable or have an altered kinase activity. The stability and kinase activity of VRK1 pathogenic variants detected two groups. One composed by variants with a reduced protein stability: R133C, R358X, L195V, G135R and R321C. The other group includes VRK1variants with a reduced kinase activity tested on several substrates: histones H3 and H2AX, p53, c-Jun, coilin and 53BP1, a DNA repair protein. VRK1 variants with reduced kinase activity are H119R, R133C, G135R, V236M, R321C and R358X. The common underlying effect of VRK1 pathogenic variants with reduced protein stability or kinase activity is a functional insufficiency of VRK1 in patients with neuromotor developmental syndromes. The G135 variant cause a defective formation of 53BP1 foci in response to DNA damage, and loss Cajal bodies assembled on coilin.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mart&#xed;n-Doncel</LastName><ForeName>Elena</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-8397-9952</Identifier><AffiliationInfo><Affiliation>Molecular Mechanisms of Cancer Program, Instituto de Biolog&#xed;a Molecular y Celular del C&#xe1;ncer, Consejo Superior de Investigaciones Cient&#xed;ficas (CSIC) - Universidad de Salamanca, Salamanca, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n Biom&#xe9;dica de Salamanca (IBSAL), Hospital Universitario de Salamanca, Salamanca, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rojas</LastName><ForeName>Ana M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0003-0750-9099</Identifier><AffiliationInfo><Affiliation>Centro Andaluz de Biolog&#xed;a del Desarrollo (CABD), CSIC-Universidad Pablo de Olavide, Sevilla, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Biomedicina de Sevilla (IBIS), CSIC-Universidad de Sevilla, Hospital Universitario Virgen del Roc&#xed;o, Sevilla, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cantarero</LastName><ForeName>Lara</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-5196-5262</Identifier><AffiliationInfo><Affiliation>Molecular Mechanisms of Cancer Program, Instituto de Biolog&#xed;a Molecular y Celular del C&#xe1;ncer, Consejo Superior de Investigaciones Cient&#xed;ficas (CSIC) - Universidad de Salamanca, Salamanca, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n Biom&#xe9;dica de Salamanca (IBSAL), Hospital Universitario de Salamanca, Salamanca, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratorio de Neurogen&#xe9;tica y Medicina Molecular, Institut de Recerca Sant Joan de D&#xe9;u, Esplugues de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lazo</LastName><ForeName>Pedro A</ForeName><Initials>PA</Initials><Identifier Source="ORCID">0000-0001-8997-3025</Identifier><AffiliationInfo><Affiliation>Molecular Mechanisms of Cancer Program, Instituto de Biolog&#xed;a Molecular y Celular del C&#xe1;ncer, Consejo Superior de Investigaciones Cient&#xed;ficas (CSIC) - Universidad de Salamanca, Salamanca, Spain. pedro.lazo@csic.es.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Investigaci&#xf3;n Biom&#xe9;dica de Salamanca (IBSAL), Hospital Universitario de Salamanca, Salamanca, Spain. pedro.lazo@csic.es.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>09</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006657">Histones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D017346">Protein Serine-Threonine Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C109890">VRK1 protein, human</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C580383">Pontocerebellar Hypoplasia</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002526" MajorTopicYN="N">Cerebellar Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020541" MajorTopicYN="N">Coiled Bodies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004249" MajorTopicYN="N">DNA Damage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030541" MajorTopicYN="N">Databases, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006657" MajorTopicYN="N">Histones</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006720" MajorTopicYN="N">Homozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047908" MajorTopicYN="N">Intracellular Signaling Peptides and Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008831" MajorTopicYN="N">Microcephaly</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009134" MajorTopicYN="N">Muscular Atrophy, Spinal</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009468" MajorTopicYN="N">Neuromuscular Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017346" MajorTopicYN="N">Protein Serine-Threonine Kinases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055550" MajorTopicYN="N">Protein Stability</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31527692</ArticleId><ArticleId IdType="pmc">PMC6746721</ArticleId><ArticleId IdType="doi">10.1038/s41598-019-49821-7</ArticleId><ArticleId IdType="pii">10.1038/s41598-019-49821-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kang TH, et al. Mitotic histone H3 phosphorylation by vaccinia-related kinase 1 in mammalian cells. Mol. Cell. Biol. 2007;27:8533&#x2013;8546. doi: 10.1128/MCB.00018-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.00018-07</ArticleId><ArticleId IdType="pmc">PMC2169395</ArticleId><ArticleId IdType="pubmed">17938195</ArticleId></ArticleIdList></Reference><Reference><Citation>Salzano M, Sanz-Garcia M, Monsalve DM, Moura DS, Lazo PA. VRK1 chromatin kinase phosphorylates H2AX and is required for foci formation induced by DNA damage. Epigenetics. 2015;10:373&#x2013;383. doi: 10.1080/15592294.2015.1028708.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15592294.2015.1028708</ArticleId><ArticleId IdType="pmc">PMC4623420</ArticleId><ArticleId IdType="pubmed">25923214</ArticleId></ArticleIdList></Reference><Reference><Citation>Moura DS, Campillo-Marcos I, Vazquez-Cedeira M, Lazo PA. VRK1 and AURKB form a complex that cross inhibit their kinase activity and the phosphorylation of histone H3 in the progression of mitosis. Cell Mol Life Sci. 2018;76:2591&#x2013;2611. doi: 10.1007/s00018-018-2746-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-018-2746-7</ArticleId><ArticleId IdType="pmc">PMC6003988</ArticleId><ArticleId IdType="pubmed">29340707</ArticleId></ArticleIdList></Reference><Reference><Citation>Aihara H, et al. Histone H2A T120 Phosphorylation Promotes Oncogenic Transformation via Upregulation of Cyclin D1. Mol Cell. 2016;64:176&#x2013;188. doi: 10.1016/j.molcel.2016.09.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2016.09.012</ArticleId><ArticleId IdType="pubmed">27716482</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Borges S, Lazo PA. The human vaccinia-related kinase 1 (VRK1) phosphorylates threonine-18 within the mdm-2 binding site of the p53 tumour suppressor protein. Oncogene. 2000;19:3656&#x2013;3664. doi: 10.1038/sj.onc.1203709.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1203709</ArticleId><ArticleId IdType="pubmed">10951572</ArticleId></ArticleIdList></Reference><Reference><Citation>Vega FM, Sevilla A, Lazo PA. p53 Stabilization and accumulation induced by human vaccinia-related kinase 1. Mol. Cell. Biol. 2004;24:10366&#x2013;10380. doi: 10.1128/MCB.24.23.10366-10380.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.24.23.10366-10380.2004</ArticleId><ArticleId IdType="pmc">PMC529057</ArticleId><ArticleId IdType="pubmed">15542844</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevilla A, Santos CR, Barcia R, Vega FM, Lazo PA. c-Jun phosphorylation by the human vaccinia-related kinase 1 (VRK1) and its cooperation with the N-terminal kinase of c-Jun (JNK) Oncogene. 2004;23:8950&#x2013;8958. doi: 10.1038/sj.onc.1208015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1208015</ArticleId><ArticleId IdType="pubmed">15378002</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevilla A, Santos CR, Vega FM, Lazo PA. Human vaccinia-related kinase 1 (VRK1) activates the ATF2 transcriptional activity by novel phosphorylation on Thr-73 and Ser-62 and cooperates with JNK. J. Biol. Chem. 2004;279:27458&#x2013;27465. doi: 10.1074/jbc.M401009200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M401009200</ArticleId><ArticleId IdType="pubmed">15105425</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang TH, Park DY, Kim W, Kim KT. VRK1 phosphorylates CREB and mediates CCND1 expression. J. Cell. Sci. 2008;121:3035&#x2013;3041. doi: 10.1242/jcs.026757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.026757</ArticleId><ArticleId IdType="pubmed">18713830</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashiguchi T, et al. Phosphorylation of Farnesoid X Receptor at Serine 154 Links Ligand Activation With Degradation. Mol Endocrinol. 2016;30:1070&#x2013;1080. doi: 10.1210/me.2016-1105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/me.2016-1105</ArticleId><ArticleId IdType="pmc">PMC5045495</ArticleId><ArticleId IdType="pubmed">27571290</ArticleId></ArticleIdList></Reference><Reference><Citation>Monsalve DM, et al. VRK1 phosphorylates and protects NBS1 from ubiquitination and proteasomal degradation in response to DNA damage. BBA Mol. Cell Res. 2016;1863:760&#x2013;769. doi: 10.1016/j.bbamcr.2016.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamcr.2016.02.005</ArticleId><ArticleId IdType="pubmed">26869104</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanz-Garcia M, Monsalve DM, Sevilla A, Lazo PA. Vaccinia-related Kinase 1 (VRK1) is an upstream nucleosomal kinase required for the assembly of 53BP1 foci in response to ionizing radiation-induced DNA damage. J. Biol. Chem. 2012;287:23757&#x2013;23768. doi: 10.1074/jbc.M112.353102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.353102</ArticleId><ArticleId IdType="pmc">PMC3390650</ArticleId><ArticleId IdType="pubmed">22621922</ArticleId></ArticleIdList></Reference><Reference><Citation>Valbuena A, Lopez-Sanchez I, Lazo PA. Human VRK1 is an early response gene and its loss causes a block in cell cycle progression. PLoS One. 2008;3:e1642. doi: 10.1371/journal.pone.0001642.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0001642</ArticleId><ArticleId IdType="pmc">PMC2241669</ArticleId><ArticleId IdType="pubmed">18286197</ArticleId></ArticleIdList></Reference><Reference><Citation>Valbuena A, Sanz-Garcia M, Lopez-Sanchez I, Vega FM, Lazo PA. Roles of VRK1 as a new player in the control of biological processes required for cell division. Cell. Signal. 2011;23:1267&#x2013;1272. doi: 10.1016/j.cellsig.2011.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellsig.2011.04.002</ArticleId><ArticleId IdType="pubmed">21514377</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanz-Garcia, M. et al. In Emerging Signaling Pathways in Tumor Biology (ed. Lazo, P. A.) 135&#x2013;156 (Transworld Research Networks, 2010).</Citation></Reference><Reference><Citation>Campillo-Marcos I, Lazo PA. Implication of the VRK1 chromatin kinase in the signaling responses to DNA damage: a therapeutic target? Cell Mol Life Sci. 2018;75:2375&#x2013;2388. doi: 10.1007/s00018-018-2811-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-018-2811-2</ArticleId><ArticleId IdType="pmc">PMC5986855</ArticleId><ArticleId IdType="pubmed">29679095</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi YH, Lim JK, Jeong MW, Kim KT. HnRNP A1 phosphorylated by VRK1 stimulates telomerase and its binding to telomeric DNA sequence. Nucleic Acids Res. 2012;40:8499&#x2013;8518. doi: 10.1093/nar/gks634.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gks634</ArticleId><ArticleId IdType="pmc">PMC3458570</ArticleId><ArticleId IdType="pubmed">22740652</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Sanchez I, Sanz-Garcia M, Lazo PA. Plk3 interacts with and specifically phosphorylates VRK1 in Ser342, a downstream target in a pathway that induces Golgi fragmentation. Mol. Cell. Biol. 2009;29:1189&#x2013;1201. doi: 10.1128/MCB.01341-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.01341-08</ArticleId><ArticleId IdType="pmc">PMC2643820</ArticleId><ArticleId IdType="pubmed">19103756</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantarero L, et al. VRK1 regulates Cajal body dynamics and protects coilin from proteasomal degradation in cell cycle. Sci Rep. 2015;5:10543. doi: 10.1038/srep10543.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep10543</ArticleId><ArticleId IdType="pmc">PMC4464288</ArticleId><ArticleId IdType="pubmed">26068304</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichols RJ, Wiebe MS, Traktman P. The vaccinia-related kinases phosphorylate the N&#x2019; terminus of BAF, regulating its interaction with DNA and its retention in the nucleus. Mol. Biol. Cell. 2006;17:2451&#x2013;2464. doi: 10.1091/mbc.E05-12-1179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.E05-12-1179</ArticleId><ArticleId IdType="pmc">PMC1446082</ArticleId><ArticleId IdType="pubmed">16495336</ArticleId></ArticleIdList></Reference><Reference><Citation>Bianchi FT, Berto GE, Di Cunto F. Impact of DNA repair and stability defects on cortical development. Cell Mol Life Sci. 2018;75:3963&#x2013;3976. doi: 10.1007/s00018-018-2900-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-018-2900-2</ArticleId><ArticleId IdType="pubmed">30116853</ArticleId></ArticleIdList></Reference><Reference><Citation>Renbaum P, et al. Spinal muscular atrophy with pontocerebellar hypoplasia is caused by a mutation in the VRK1 gene. Am. J. Hum. Genet. 2009;85:281&#x2013;289. doi: 10.1016/j.ajhg.2009.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2009.07.006</ArticleId><ArticleId IdType="pmc">PMC2725266</ArticleId><ArticleId IdType="pubmed">19646678</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanz-Garcia M, et al. Substrate profiling of human vaccinia-related kinases identifies coilin, a Cajal body nuclear protein, as a phosphorylation target with neurological implications. J. Proteomics. 2011;75:548&#x2013;560. doi: 10.1016/j.jprot.2011.08.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jprot.2011.08.019</ArticleId><ArticleId IdType="pubmed">21920476</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzaga-Jauregui C, et al. Mutations in VRK1 associated with complex motor and sensory axonal neuropathy plus microcephaly. JAMA Neurol. 2013;70:1491&#x2013;1498. doi: 10.1001/jamaneurol.2013.4598.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.4598</ArticleId><ArticleId IdType="pmc">PMC4039291</ArticleId><ArticleId IdType="pubmed">24126608</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen TP, Biliciler S, Wiszniewski W, Sheikh K. Expanding Phenotype of VRK1 Mutations in Motor Neuron Disease. J Clin Neuromuscul Dis. 2015;17:69&#x2013;71. doi: 10.1097/CND.0000000000000096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CND.0000000000000096</ArticleId><ArticleId IdType="pmc">PMC4829393</ArticleId><ArticleId IdType="pubmed">26583493</ArticleId></ArticleIdList></Reference><Reference><Citation>Najmabadi H, et al. Deep sequencing reveals 50 novel genes for recessive cognitive disorders. Nature. 2011;478:57&#x2013;63. doi: 10.1038/nature10423.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10423</ArticleId><ArticleId IdType="pubmed">21937992</ArticleId></ArticleIdList></Reference><Reference><Citation>Harms MB, et al. Dominant spinal muscular atrophy with lower extremity predominance: linkage to 14q32. Neurology. 2010;75:539&#x2013;546. doi: 10.1212/WNL.0b013e3181ec800c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181ec800c</ArticleId><ArticleId IdType="pmc">PMC2918478</ArticleId><ArticleId IdType="pubmed">20697106</ArticleId></ArticleIdList></Reference><Reference><Citation>Karczewski, K. J. et al. Variation across 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance across human protein-coding genes. bioRxiv, 531210, 10.1101/531210 (2019).</Citation></Reference><Reference><Citation>Scheeff ED, Eswaran J, Bunkoczi G, Knapp S, Manning G. Structure of the pseudokinase VRK3 reveals a degraded catalytic site, a highly conserved kinase fold, and a putative regulatory binding site. Structure. 2009;17:128&#x2013;138. doi: 10.1016/j.str.2008.10.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.str.2008.10.018</ArticleId><ArticleId IdType="pmc">PMC2639636</ArticleId><ArticleId IdType="pubmed">19141289</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin J, et al. NMR solution structure of human vaccinia-related kinase 1 (VRK1) reveals the C-terminal tail essential for its structural stability and autocatalytic activity. J. Biol. Chem. 2011;286:22131&#x2013;22138. doi: 10.1074/jbc.M110.200162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.200162</ArticleId><ArticleId IdType="pmc">PMC3121357</ArticleId><ArticleId IdType="pubmed">21543316</ArticleId></ArticleIdList></Reference><Reference><Citation>Studer Romain A., Opperdoes Fred R., Nicolaes Gerry A. F., Mulder Andr&#xe9; B., Mulder Ren&#xe9;. Understanding the functional difference between growth arrest-specific protein 6 and protein S: an evolutionary approach. Open Biology. 2014;4(10):140121. doi: 10.1098/rsob.140121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rsob.140121</ArticleId><ArticleId IdType="pmc">PMC4221892</ArticleId><ArticleId IdType="pubmed">25339693</ArticleId></ArticleIdList></Reference><Reference><Citation>Barcia R, Lopez-Borges S, Vega FM, Lazo PA. Kinetic properties of p53 phosphorylation by the human vaccinia-related kinase 1. Arch. Biochem. Biophys. 2002;399:1&#x2013;5. doi: 10.1006/abbi.2001.2746.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/abbi.2001.2746</ArticleId><ArticleId IdType="pubmed">11883897</ArticleId></ArticleIdList></Reference><Reference><Citation>Barcia-Sanjurjo I, Vazquez-Cedeira M, Barcia R, Lazo PA. Sensitivity of the kinase activity of human vaccinia-related kinase proteins to toxic metals. J. Biol. Inorg. Chem. 2013;18:473&#x2013;482. doi: 10.1007/s00775-013-0992-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00775-013-0992-6</ArticleId><ArticleId IdType="pubmed">23483238</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Sanchez I, et al. VRK1 interacts with p53 forming a basal complex that is activated by UV-induced DNA damage. FEBS Lett. 2014;588:692&#x2013;700. doi: 10.1016/j.febslet.2014.01.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2014.01.040</ArticleId><ArticleId IdType="pubmed">24492002</ArticleId></ArticleIdList></Reference><Reference><Citation>Valbuena A, Castro-Obregon S, Lazo PA. Downregulation of VRK1 by p53 in Response to DNA Damage Is Mediated by the Autophagic Pathway. PLoS One. 2011;6:e17320. doi: 10.1371/journal.pone.0017320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0017320</ArticleId><ArticleId IdType="pmc">PMC3046209</ArticleId><ArticleId IdType="pubmed">21386980</ArticleId></ArticleIdList></Reference><Reference><Citation>Ip YT, Davis RJ. Signal transduction by the c-Jun N-terminal kinase (JNK)&#x2013;from inflammation to development. Curr Opin Cell Biol. 1998;10:205&#x2013;219. doi: 10.1016/S0955-0674(98)80143-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0955-0674(98)80143-9</ArticleId><ArticleId IdType="pubmed">9561845</ArticleId></ArticleIdList></Reference><Reference><Citation>Salzano M, et al. Vaccinia-related kinase 1 (VRK1) confers resistance to DNA-damaging agents in human breast cancer by affecting DNA damage response. Oncotarget. 2014;5:1770&#x2013;1778. doi: 10.18632/oncotarget.1678.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.1678</ArticleId><ArticleId IdType="pmc">PMC4039124</ArticleId><ArticleId IdType="pubmed">24731990</ArticleId></ArticleIdList></Reference><Reference><Citation>Dundr M, et al. In vivo kinetics of Cajal body components. J. Cell. Biol. 2004;164:831&#x2013;842. doi: 10.1083/jcb.200311121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200311121</ArticleId><ArticleId IdType="pmc">PMC1630494</ArticleId><ArticleId IdType="pubmed">15024031</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, Ka S, Kim S, Park Y, Kang S. p80 coilin, a coiled body-specific protein, interacts with ataxin-1, the SCA1 gene product. Biochim. Biophys. Acta. 2003;1638:35&#x2013;42. doi: 10.1016/S0925-4439(03)00038-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0925-4439(03)00038-3</ArticleId><ArticleId IdType="pubmed">12757932</ArticleId></ArticleIdList></Reference><Reference><Citation>Han KJ, et al. Monoubiquitination of survival motor neuron regulates its cellular localization and Cajal body integrity. Hum Mol Genet. 2016;25:1392&#x2013;1405. doi: 10.1093/hmg/ddw021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddw021</ArticleId><ArticleId IdType="pmc">PMC4787908</ArticleId><ArticleId IdType="pubmed">26908624</ArticleId></ArticleIdList></Reference><Reference><Citation>Hearst SM, et al. Cajal-body formation correlates with differential coilin phosphorylation in primary and transformed cell lines. J. Cell Sci. 2009;122:1872&#x2013;1881. doi: 10.1242/jcs.044040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.044040</ArticleId><ArticleId IdType="pmc">PMC2684838</ArticleId><ArticleId IdType="pubmed">19435804</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert Michael D., Poole Aaron R. Towards an understanding of regulating Cajal body activity by protein modification. RNA Biology. 2016;14(6):761&#x2013;778. doi: 10.1080/15476286.2016.1243649.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15476286.2016.1243649</ArticleId><ArticleId IdType="pmc">PMC5519237</ArticleId><ArticleId IdType="pubmed">27819531</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert MD, Szymczyk PW, Shpargel KB, Matera AG. Coilin forms the bridge between Cajal bodies and SMN, the spinal muscular atrophy protein. Genes Dev. 2001;15:2720&#x2013;2729. doi: 10.1101/gad.908401.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.908401</ArticleId><ArticleId IdType="pmc">PMC312817</ArticleId><ArticleId IdType="pubmed">11641277</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin HZ, et al. Slow development of ALS-like spinal cord pathology in mutant valosin-containing protein gene knock-in mice. Cell Death Dis. 2012;3:e374. doi: 10.1038/cddis.2012.115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2012.115</ArticleId><ArticleId IdType="pmc">PMC3434652</ArticleId><ArticleId IdType="pubmed">22898872</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams KL, Solski JA, Nicholson GA, Blair IP. Mutation analysis of VCP in familial and sporadic amyotrophic lateral sclerosis. Neurobiol Aging. 2012;33:1488 e1415&#x2013;1486. doi: 10.1016/j.neurobiolaging.2011.11.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.11.022</ArticleId><ArticleId IdType="pubmed">22196955</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoll M, et al. Novel motor phenotypes in patients with VRK1 mutations without pontocerebellar hypoplasia. Neurology. 2016;87:65&#x2013;70. doi: 10.1212/WNL.0000000000002813.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002813</ArticleId><ArticleId IdType="pmc">PMC4932233</ArticleId><ArticleId IdType="pubmed">27281532</ArticleId></ArticleIdList></Reference><Reference><Citation>Campillo-Marcos I, Lazo PA. Olaparib and ionizing radiation trigger a cooperative DNA-damage repair response that is impaired by depletion of the VRK1 chromatin kinase. J Exp Clin Cancer Res. 2019;38:203. doi: 10.1186/s13046-019-1204-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13046-019-1204-1</ArticleId><ArticleId IdType="pmc">PMC6525392</ArticleId><ArticleId IdType="pubmed">31101118</ArticleId></ArticleIdList></Reference><Reference><Citation>Moura DS, et al. Oncogenic Sox2 regulates and cooperates with VRK1 in cell cycle progression and differentiation. Sci Rep. 2016;6:28532. doi: 10.1038/srep28532.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep28532</ArticleId><ArticleId IdType="pmc">PMC4917848</ArticleId><ArticleId IdType="pubmed">27334688</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinograd-Byk H, et al. The Spinal Muscular Atrophy with Pontocerebellar Hypoplasia Gene VRK1 Regulates Neuronal Migration through an Amyloid-beta Precursor Protein-Dependent Mechanism. J Neurosci. 2015;35:936&#x2013;942. doi: 10.1523/JNEUROSCI.1998-14.2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1998-14.2015</ArticleId><ArticleId IdType="pmc">PMC6605533</ArticleId><ArticleId IdType="pubmed">25609612</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiebe MS, Nichols RJ, Molitor TP, Lindgren JK, Traktman P. Mice deficient in the serine/threonine protein kinase VRK1 are infertile due to a progressive loss of spermatogonia. Biol. Reprod. 2010;82:182&#x2013;193. doi: 10.1095/biolreprod.109.079095.</Citation><ArticleIdList><ArticleId IdType="doi">10.1095/biolreprod.109.079095</ArticleId><ArticleId IdType="pmc">PMC2802121</ArticleId><ArticleId IdType="pubmed">19696012</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinograd-Byk H, Renbaum P, Levy-Lahad E. Vrk1 partial Knockdown in Mice Results in Reduced Brain Weight and Mild Motor Dysfunction, and Indicates Neuronal VRK1 Target Pathways. Sci Rep. 2018;8:11265. doi: 10.1038/s41598-018-29215-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-29215-x</ArticleId><ArticleId IdType="pmc">PMC6062608</ArticleId><ArticleId IdType="pubmed">30050127</ArticleId></ArticleIdList></Reference><Reference><Citation>Park CH, et al. Protein kinase Cdelta regulates vaccinia-related kinase 1 in DNA damage-induced apoptosis. Mol. Biol. Cell. 2011;22:1398&#x2013;1408. doi: 10.1091/mbc.E10-08-0717.</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.E10-08-0717</ArticleId><ArticleId IdType="pmc">PMC3078082</ArticleId><ArticleId IdType="pubmed">21346188</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngow YS, Rajan S, Ye H, Yoon HS. Crystal structure of human Vaccinia-related kinase 1 (VRK1) in complex with AMP-PNP, a non-hydrolysable ATP analog. Protein Sci. 2019;28:524&#x2013;532. doi: 10.1002/pro.3552.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pro.3552</ArticleId><ArticleId IdType="pmc">PMC6371211</ArticleId><ArticleId IdType="pubmed">30461091</ArticleId></ArticleIdList></Reference><Reference><Citation>Enwerem II, Wu G, Yu YT, Hebert MD. Cajal body proteins differentially affect the processing of box C/D scaRNPs. PLoS One. 2015;10:e0122348. doi: 10.1371/journal.pone.0122348.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0122348</ArticleId><ArticleId IdType="pmc">PMC4395269</ArticleId><ArticleId IdType="pubmed">25875178</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaytow Helena, Huang Yu-Ting, Gillingwater Thomas H., Faller Kiterie M. E. The role of survival motor neuron protein (SMN) in protein homeostasis. Cellular and Molecular Life Sciences. 2018;75(21):3877&#x2013;3894. doi: 10.1007/s00018-018-2849-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-018-2849-1</ArticleId><ArticleId IdType="pmc">PMC6182345</ArticleId><ArticleId IdType="pubmed">29872871</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez CE, Cunningham D, Chandler DS. SMN regulation in SMA and in response to stress: new paradigms and therapeutic possibilities. Hum Genet. 2017;136:1173&#x2013;1191. doi: 10.1007/s00439-017-1835-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00439-017-1835-2</ArticleId><ArticleId IdType="pmc">PMC6201753</ArticleId><ArticleId IdType="pubmed">28852871</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr HT. SCA1-phosphorylation, a regulator of Ataxin-1 function and pathogenesis. Prog Neurobiol. 2012;99:179&#x2013;185. doi: 10.1016/j.pneurobio.2012.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2012.04.003</ArticleId><ArticleId IdType="pmc">PMC3408849</ArticleId><ArticleId IdType="pubmed">22531670</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorgensen ND, et al. Phosphorylation of ATXN1 at Ser776 in the cerebellum. J Neurochem. 2009;110:675&#x2013;686. doi: 10.1111/j.1471-4159.2009.06164.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2009.06164.x</ArticleId><ArticleId IdType="pmc">PMC2754139</ArticleId><ArticleId IdType="pubmed">19500214</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr HT, et al. Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1. Nat Genet. 1993;4:221&#x2013;226. doi: 10.1038/ng0793-221.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng0793-221</ArticleId><ArticleId IdType="pubmed">8358429</ArticleId></ArticleIdList></Reference><Reference><Citation>Koppers M, et al. VCP mutations in familial and sporadic amyotrophic lateral sclerosis. Neurobiol Aging. 2012;33:837 e837&#x2013;813. doi: 10.1016/j.neurobiolaging.2011.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.10.006</ArticleId><ArticleId IdType="pubmed">22078486</ArticleId></ArticleIdList></Reference><Reference><Citation>Price PL, Morderer D, Rossoll W. RNP Assembly Defects in Spinal Muscular Atrophy. Adv Neurobiol. 2018;20:143&#x2013;171. doi: 10.1007/978-3-319-89689-2_6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-319-89689-2_6</ArticleId><ArticleId IdType="pubmed">29916019</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao M, Kim JR, van Bruggen R, Park J. RNA-Binding Proteins in Amyotrophic Lateral Sclerosis. Mol Cells. 2018;41:818&#x2013;829. doi: 10.14348/molcells.2018.0243.</Citation><ArticleIdList><ArticleId IdType="doi">10.14348/molcells.2018.0243</ArticleId><ArticleId IdType="pmc">PMC6182225</ArticleId><ArticleId IdType="pubmed">30157547</ArticleId></ArticleIdList></Reference><Reference><Citation>Mon AM, MacKinnon AC, Jr., Traktman P. Overexpression of the VRK1 kinase, which is associated with breast cancer, induces a mesenchymal to epithelial transition in mammary epithelial cells. PLoS One. 2018;13:e0203397. doi: 10.1371/journal.pone.0203397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0203397</ArticleId><ArticleId IdType="pmc">PMC6122820</ArticleId><ArticleId IdType="pubmed">30180179</ArticleId></ArticleIdList></Reference><Reference><Citation>Cobos Samantha N., Bennett Seth A., Torrente Mariana P. The impact of histone post-translational modifications in neurodegenerative diseases. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2019;1865(8):1982&#x2013;1991. doi: 10.1016/j.bbadis.2018.10.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2018.10.019</ArticleId><ArticleId IdType="pmc">PMC6475498</ArticleId><ArticleId IdType="pubmed">30352259</ArticleId></ArticleIdList></Reference><Reference><Citation>Berson A, Nativio R, Berger SL, Bonini NM. Epigenetic Regulation in Neurodegenerative Diseases. Trends Neurosci. 2018;41:587&#x2013;598. doi: 10.1016/j.tins.2018.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2018.05.005</ArticleId><ArticleId IdType="pmc">PMC6174532</ArticleId><ArticleId IdType="pubmed">29885742</ArticleId></ArticleIdList></Reference><Reference><Citation>McKinnon PJ, Caldecott KW. DNA strand break repair and human genetic disease. Annu Rev Genomics Hum Genet. 2007;8:37&#x2013;55. doi: 10.1146/annurev.genom.7.080505.115648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.genom.7.080505.115648</ArticleId><ArticleId IdType="pubmed">17887919</ArticleId></ArticleIdList></Reference><Reference><Citation>Sepe S, Payan-Gomez C, Milanese C, Hoeijmakers JH, Mastroberardino PG. Nucleotide excision repair in chronic neurodegenerative diseases. DNA Repair (Amst) 2013;12:568&#x2013;577. doi: 10.1016/j.dnarep.2013.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dnarep.2013.04.009</ArticleId><ArticleId IdType="pubmed">23726220</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuura S, Kobayashi J, Tauchi H, Komatsu K. Nijmegen breakage syndrome and DNA double strand break repair by NBS1 complex. Adv Biophys. 2004;38:65&#x2013;80. doi: 10.1016/S0065-227X(04)80076-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0065-227X(04)80076-5</ArticleId><ArticleId IdType="pubmed">15476893</ArticleId></ArticleIdList></Reference><Reference><Citation>Natale V, Raquer H. Xeroderma pigmentosum-Cockayne syndrome complex. Orphanet J Rare Dis. 2017;12:65. doi: 10.1186/s13023-017-0616-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13023-017-0616-2</ArticleId><ArticleId IdType="pmc">PMC5379700</ArticleId><ArticleId IdType="pubmed">28376890</ArticleId></ArticleIdList></Reference><Reference><Citation>Penndorf D, Witte OW, Kretz A. DNA plasticity and damage in amyotrophic lateral sclerosis. Neural Regen Res. 2018;13:173&#x2013;180. doi: 10.4103/1673-5374.226377.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.226377</ArticleId><ArticleId IdType="pmc">PMC5879878</ArticleId><ArticleId IdType="pubmed">29557356</ArticleId></ArticleIdList></Reference><Reference><Citation>Digweed M, Sperling K. Nijmegen breakage syndrome: clinical manifestation of defective response to DNA double-strand breaks. DNA Repair (Amst) 2004;3:1207&#x2013;1217. doi: 10.1016/j.dnarep.2004.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dnarep.2004.03.004</ArticleId><ArticleId IdType="pubmed">15279809</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan R, Wu J, Baloue KK, Crowe DL. Regulation of the Nijmegen breakage syndrome 1 gene NBS1 by c-myc, p53 and coactivators mediates estrogen protection from DNA damage in breast cancer cells. Int J Oncol. 2013;42:712&#x2013;720. doi: 10.3892/ijo.2012.1757.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijo.2012.1757</ArticleId><ArticleId IdType="pubmed">23291854</ArticleId></ArticleIdList></Reference><Reference><Citation>Valbuena A, Vega FM, Blanco S, Lazo PA. p53 downregulates its activating vaccinia-related kinase 1, forming a new autoregulatory loop. Mol. Cell. Biol. 2006;26:4782&#x2013;4793. doi: 10.1128/MCB.00069-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.00069-06</ArticleId><ArticleId IdType="pmc">PMC1489172</ArticleId><ArticleId IdType="pubmed">16782868</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz JB, et al. Diagnosis and treatment of Friedreich ataxia: a European perspective. Nat Rev Neurol. 2009;5:222&#x2013;234. doi: 10.1038/nrneurol.2009.26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2009.26</ArticleId><ArticleId IdType="pubmed">19347027</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobbin MM, et al. SIRT1 collaborates with ATM and HDAC1 to maintain genomic stability in neurons. Nat Neurosci. 2013;16:1008&#x2013;1015. doi: 10.1038/nn.3460.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3460</ArticleId><ArticleId IdType="pmc">PMC4758134</ArticleId><ArticleId IdType="pubmed">23852118</ArticleId></ArticleIdList></Reference><Reference><Citation>Addis L, et al. Analysis of rare copy number variation in absence epilepsies. Neurol Genet. 2016;2:e56. doi: 10.1212/NXG.0000000000000056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXG.0000000000000056</ArticleId><ArticleId IdType="pmc">PMC4830185</ArticleId><ArticleId IdType="pubmed">27123475</ArticleId></ArticleIdList></Reference><Reference><Citation>Borlot F, Regan BM, Bassett AS, Stavropoulos DJ, Andrade DM. Prevalence of Pathogenic Copy Number Variation in Adults With Pediatric-Onset Epilepsy and Intellectual Disability. JAMA Neurol. 2017;74:1301&#x2013;1311. doi: 10.1001/jamaneurol.2017.1775.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.1775</ArticleId><ArticleId IdType="pmc">PMC5710585</ArticleId><ArticleId IdType="pubmed">28846756</ArticleId></ArticleIdList></Reference><Reference><Citation>McMichael G, et al. Rare copy number variation in cerebral palsy. Eur J Hum Genet. 2014;22:40&#x2013;45. doi: 10.1038/ejhg.2013.93.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ejhg.2013.93</ArticleId><ArticleId IdType="pmc">PMC3865415</ArticleId><ArticleId IdType="pubmed">23695280</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskoui M, et al. Clinically relevant copy number variations detected in cerebral palsy. Nat Commun. 2015;6:7949. doi: 10.1038/ncomms8949.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms8949</ArticleId><ArticleId IdType="pmc">PMC4532872</ArticleId><ArticleId IdType="pubmed">26236009</ArticleId></ArticleIdList></Reference><Reference><Citation>Segel R, et al. Copy number variations in cryptogenic cerebral palsy. Neurology. 2015;84:1660&#x2013;1668. doi: 10.1212/WNL.0000000000001494.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001494</ArticleId><ArticleId IdType="pubmed">25817843</ArticleId></ArticleIdList></Reference><Reference><Citation>Schymkowitz J, et al. The FoldX web server: an online force field. Nucleic Acids Res. 2005;33:W382&#x2013;388. doi: 10.1093/nar/gki387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gki387</ArticleId><ArticleId IdType="pmc">PMC1160148</ArticleId><ArticleId IdType="pubmed">15980494</ArticleId></ArticleIdList></Reference><Reference><Citation>Vazquez-Cedeira M, Barcia-Sanjurjo I, Sanz-Garcia M, Barcia R, Lazo PA. Differential Inhibitor Sensitivity between Human Kinases VRK1 and VRK2. PLoS One. 2011;6:e23235. doi: 10.1371/journal.pone.0023235.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0023235</ArticleId><ArticleId IdType="pmc">PMC3150407</ArticleId><ArticleId IdType="pubmed">21829721</ArticleId></ArticleIdList></Reference><Reference><Citation>Rappold I, Iwabuchi K, Date T, Chen J. Tumor suppressor p53 binding protein 1 (53BP1) is involved in DNA damage-signaling pathways. J. Cell. Biol. 2001;153:613&#x2013;620. doi: 10.1083/jcb.153.3.613.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.153.3.613</ArticleId><ArticleId IdType="pmc">PMC2190566</ArticleId><ArticleId IdType="pubmed">11331310</ArticleId></ArticleIdList></Reference><Reference><Citation>Milne DM, Campbell DG, Caudwell FB, Meek DW. Phosphorylation of tumor suppressor protein p53 by mitogen-activated protein kinase. J. Biol. Chem. 1994;269:9253&#x2013;9260.</Citation><ArticleIdList><ArticleId IdType="pubmed">7510706</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos CR, Vega FM, Blanco S, Barcia R, Lazo PA. The vaccinia virus B1R kinase induces p53 downregulation by an Mdm2-dependent mechanism. Virology. 2004;328:254&#x2013;265. doi: 10.1016/j.virol.2004.08.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2004.08.013</ArticleId><ArticleId IdType="pubmed">15464845</ArticleId></ArticleIdList></Reference><Reference><Citation>Milne DM, Palmer RH, Campbell DG, Meek DW. Phosphorylation of the p53 tumour-suppressor protein at the three N-terminal sites by a novel casein kinase I-like enzyme. Oncogene. 1992;7:1361&#x2013;1369.</Citation><ArticleIdList><ArticleId IdType="pubmed">1620549</ArticleId></ArticleIdList></Reference><Reference><Citation>Bremer, M. &amp; Doerge, R. M. Statistics at the bench: a step-by step handbook for biologists. (Cold Spring Harbor Laboratory Press, 2009).</Citation></Reference><Reference><Citation>Reches Adi, Hiersch Liran, Simchoni Sharon, Barel Dalit, Greenberg Rotem, Ben Sira Liat, Malinger Gustavo, Yaron Yuval. Whole-exome sequencing in fetuses with central nervous system abnormalities. Journal of Perinatology. 2018;38(10):1301&#x2013;1308. doi: 10.1038/s41372-018-0199-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41372-018-0199-3</ArticleId><ArticleId IdType="pubmed">30108342</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>